FibroGen Inc. Releases Proforma Financials Following $220 Million Sale of FibroGen China to AstraZeneca
FibroGen Inc. has released its unaudited pro forma condensed consolidated financial statements in connection with its recent transaction involving the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited. The transaction, valued at approximately $220 million, includes $85 million in enterprise value and about $135 million in net cash held in China. The financial statements, prepared in accordance with Article 11 of Regulation S-X, illustrate the impact of this transaction on FibroGen's historical financials. At the closing, FibroGen also repaid its $81 million senior secured term loan with Morgan Stanley Tactical Value and entered into a transition services agreement, among other customary agreements. The pro forma statements provide insights into the financial adjustments and anticipated outcomes of this significant M&A activity.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FibroGen Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000921299-25-000007), on September 05, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。